We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OrthoPediatrics (KIDS) Soars 7.5%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
OrthoPediatrics (KIDS - Free Report) shares rallied 7.5% in the last trading session to close at $35.36. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.8% gain over the past four weeks.
OrthoPediatrics was one of the attendees at the Truist Securities MedTech Conference, held on Jun 18, 2024. Besides, the company delivered a remarkable 41% year-over-year growth in the 2024 first-quarter revenues, driven by the organic growth in Trauma and Deformity and Scoliosis products as well as the addition of Boston Orthotics & Prosthetics.
This maker of orthopedic devices is expected to post quarterly loss of $0.31 per share in its upcoming report, which represents a year-over-year change of -63.2%. Revenues are expected to be $52.4 million, up 32.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For OrthoPediatrics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on KIDS going forward to see if this recent jump can turn into more strength down the road.
OrthoPediatrics is part of the Zacks Medical - Instruments industry. Inogen (INGN - Free Report) , another stock in the same industry, closed the last trading session 6.1% higher at $9.75. INGN has returned 26.4% in the past month.
Inogen's consensus EPS estimate for the upcoming report has changed +8.5% over the past month to -$0.54. Compared to the company's year-ago EPS, this represents a change of -28.6%. Inogen currently boasts a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
OrthoPediatrics (KIDS) Soars 7.5%: Is Further Upside Left in the Stock?
OrthoPediatrics (KIDS - Free Report) shares rallied 7.5% in the last trading session to close at $35.36. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.8% gain over the past four weeks.
OrthoPediatrics was one of the attendees at the Truist Securities MedTech Conference, held on Jun 18, 2024. Besides, the company delivered a remarkable 41% year-over-year growth in the 2024 first-quarter revenues, driven by the organic growth in Trauma and Deformity and Scoliosis products as well as the addition of Boston Orthotics & Prosthetics.
This maker of orthopedic devices is expected to post quarterly loss of $0.31 per share in its upcoming report, which represents a year-over-year change of -63.2%. Revenues are expected to be $52.4 million, up 32.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For OrthoPediatrics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on KIDS going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
OrthoPediatrics is part of the Zacks Medical - Instruments industry. Inogen (INGN - Free Report) , another stock in the same industry, closed the last trading session 6.1% higher at $9.75. INGN has returned 26.4% in the past month.
Inogen's consensus EPS estimate for the upcoming report has changed +8.5% over the past month to -$0.54. Compared to the company's year-ago EPS, this represents a change of -28.6%. Inogen currently boasts a Zacks Rank of #3 (Hold).